BAX Earnings Date: Feb 11, 2027 (Estimated) — Baxter International Inc.
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is BAX's next earnings date?
Baxter International Inc. (BAX) is expected to report Q4 2026 earnings on Thursday, February 11, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.61 on revenue of $3.05B.
How did BAX do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Baxter International Inc. posted EPS of $0.58 versus the $0.52 estimate, a beat of 12.0%. Revenue was $2.98B against a $2.91B estimate. The stock's 1-day post-earnings move was -7.7%.
How much does BAX stock move after earnings?
BAX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.6% (up or down) in the day after earnings.
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
🤖 AI Earnings Analysis
Baxter’s Q3 beat was solid—revenue reached $3.0B versus $2.9B expected and EPS was $0.58 versus $0.52—but earnings remain below year-ago levels. Its 2026 sales outlook of 3–4% growth signals measured recovery, not a breakout.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.52 | 0.58 | +11.97% | $2.98B | ✅ Beat | -7.70% | — | — |
| 2026-07-30 | Q2 2026 | 0.37 | 0.54 | +45.95% | $2.96B | ✅ Beat | +8.00% | +10.34% | +4.68% |
| 2026-04-30 | Q1 2026 | 0.31 | 0.37 | +19.35% | $2.70B | ✅ Beat | +4.03% | +0.47% | +11.20% |
| 2026-02-12 | Q4 2025 | 0.53 | 0.44 | -16.98% | $2.97B | ❌ Miss | -16.01% | -4.18% | -21.85% |
| 2025-10-30 | Q3 2025 | 0.60 | 0.69 | +15.00% | $2.83B | ✅ Beat | -14.57% | -19.93% | -16.40% |
| 2025-07-31 | Q2 2025 | 0.61 | 0.59 | -3.28% | $2.81B | ❌ Miss | -22.41% | -19.78% | -13.02% |
| 2025-02-20 | Q4 2024 | 0.52 | 0.77 | +48.08% | $2.75B | ✅ Beat | +8.50% | +14.42% | +9.03% |
| 2024-11-08 | Q3 2024 | 0.78 | 0.80 | +2.56% | $2.70B | ✅ Beat | -3.90% | -12.06% | -11.17% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $2.91B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Medical Products And Therapies | 72.3% | $2.10B | +58.2% | $1.26B | $1.32B | $1.33B | $1.39B |
| Healthcare Systems and Technologies | 27.7% | $806.0M | +4.3% | $704.0M | $767.0M | $773.0M | $827.0M |
By region
Q3 FY26 · $2.98B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 53.6% | $1.59B | +3.3% | $1.49B | $1.54B | $1.54B | $1.55B |
| Non-US | 46.4% | $1.38B | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.